| Date | Title | |
| 10/30/08 | Vanda Pharmaceuticals Reports Third Quarter 2008 Results |  |
| 09/25/08 | Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights | |
| 09/11/08 | Vanda Pharmaceuticals Provides Update on Iloperidone | |
| 08/05/08 | Vanda Pharmaceuticals Reports Second Quarter 2008 Results | |
| 07/31/08 | Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008 | |
| 07/28/08 | Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone | |
| 06/26/08 | Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia | |
| 06/05/08 | LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests | |
| 05/22/08 | Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference | |
| 05/08/08 | Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference | |
| 05/06/08 | Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events | |
| 05/01/08 | Vanda Pharmaceuticals Reports First Quarter 2008 Results | |
| 04/24/08 | Vanda Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 1, 2008 | |
| 02/29/08 | Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiapta™ (iloperidone) | |
| 02/14/08 | Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results | |
| 02/07/08 | Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008 | |
| 01/02/08 | Vanda Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference | |
| 12/12/07 | Vanda Presents Phase III Iloperidone Efficacy Data | |
| 11/27/07 | Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application | |
| 11/08/07 | Vanda Pharmaceuticals Reports Third Quarter 2007 Results | |
| 11/02/07 | Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes | |
| 10/31/07 | Vanda Pharmaceuticals Announces Proposed $100 Million Convertible Senior Notes Offering | |
| 10/30/07 | Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties | |
| 10/30/07 | Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007 | |
| 10/23/07 | Vanda Pharmaceuticals Hires Chief Commercial Officer | |
| 10/22/07 | Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting | |
| 10/03/07 | Vanda Pharmaceuticals to Present at Natixis Bleichroeder's Hidden Gems Conference | |
| 09/27/07 | Vanda Pharmaceuticals Submits Iloperidone New Drug Application | |
| 08/02/07 | Vanda Pharmaceuticals Reports Second Quarter 2007 Results | |
| 07/26/07 | Vanda Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 2, 2007 | |
| 06/13/07 | Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo | |
| 06/08/07 | Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies | |
| 06/05/07 | Vanda Pharmaceuticals Announces Board Changes | |
| 05/24/07 | Vanda Pharmaceuticals to Present at the FBR Growth Conference 2007 | |
| 05/22/07 | Antipsychotic Iloperidone Results Show Favorable Akathisia Profile | |
| 05/18/07 | Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting | |
| 05/01/07 | Vanda Pharmaceuticals Reports First Quarter 2007 Results | |
| 04/25/07 | Vanda Pharmaceuticals to Present at the 2007 Morgan Stanley Global Healthcare Unplugged Conference | |
| 04/25/07 | Vanda Pharmaceuticals Initiates Phase II Clinical Trial for VSF-173 in Excessive Sleepiness | |
| 04/24/07 | Vanda Pharmaceuticals to Announce First Quarter 2007 Financial Results on May 1, 2007 | |
| 03/27/07 | Vanda Pharmaceuticals to Present at the Annual Meeting of the International Congress on Schizophrenia Research | |
| 02/07/07 | Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Results | |
| 01/31/07 | Vanda Pharmaceuticals to Announce Fourth Quarter 2006 Financial Results on February 7, 2007 | |
| 01/22/07 | Vanda Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters | |
| 01/19/07 | Vanda Pharmaceuticals Announces Pricing of Follow-On Offering of 3,800,000 Shares of Common Stock | |
| 01/03/07 | Vanda Pharmaceuticals to Present at the 25th Annual JPMorgan Healthcare Conference | |
| 12/07/06 | Vanda Pharmaceuticals Confirms Iloperidone Efficacy With Positive Phase III Clinical Trial Results in Schizophrenia | |
| 11/15/06 | Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results in a Phase III Transient Insomnia Clinical Trial | |
| 11/02/06 | Vanda Pharmaceuticals Reports Third Quarter 2006 Financial Results | |
| 10/25/06 | Vanda Pharmaceuticals to Announce Third Quarter 2006 Financial Results on November 2, 2006 | |
| 09/12/06 | Vanda Pharmaceuticals Announces Board Change | |
| 09/12/06 | Vanda Pharmaceuticals Announces the Appointment of H. Thomas Watkins to the Board of Directors | |
| 08/31/06 | Vanda Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2006 | |
| 08/30/06 | Vanda Pharmaceuticals Completes Enrollment for Iloperidone and VEC-162 Phase III Trials Ahead of Schedule | |
| 08/04/06 | Vanda Pharmaceuticals to Present at Bank of America 2006 Specialty Pharmaceuticals Conference | |
| 08/03/06 | Vanda Pharmaceuticals Reports Second Quarter 2006 Financial Results | |
| 07/26/06 | Vanda Pharmaceuticals to Announce Second Quarter 2006 Financial Results on August 3, 2006 | |
| 07/06/06 | Vanda Pharmaceuticals Names Dr. Paolo Baroldi Chief Medical Officer | |
| 06/23/06 | Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) Phase II Study Shows Investigational Insomnia Agent VEC-162 Improved Key Sleep Measures and Provides Immediate Phase Advance in Adults with Transient Insomnia | |
| 06/13/06 | Vanda Pharmaceuticals Announces Presentation of VEC-162 Phase II Data at Associated Professional Sleep Societies Annual Meeting | |
| 05/18/06 | Vanda Pharmaceuticals Reports First Quarter 2006 Financial Results | |
| 05/11/06 | Vanda Pharmaceuticals to Announce First Quarter 2006 Financial Results on May 18, 2006 | |
| 04/21/06 | Vanda Pharmaceuticals Inc. Announces Exercise of Over-Allotment Option by Underwriters | |
| 04/12/06 | Vanda Pharmaceuticals Inc. Announces Initial Public Offering of 5,750,000 Shares of Common Stock at $10.00 Per Share | |
RSS Feeds
